Tumor angiogenesis and molecular target therapy in ovarian carcinomas.
Growth of solid tumors depends on angiogenesis, the process by which new blood vessels develop from the endothelium of a pre-existing vasculature. Tumors promote angiogenesis by secreting various angiogeneic factors, and newly formed blood vessels induce tumor cell proliferation and invasiveness. Ovarian carcinomas have a poor prognosis, often associated with multifocal intraperitoneal dissemination accompanied by intense neovascularization. The degree of angiogenesis of ovarian carcinomas may directly influence the clinical course of the disease. Although a growing body of evidence indicates that angiogenic intensity may play a prognostic role in gynecological malignancies including ovarian carcinomas, the related biological mechanisms remain to be further elucidated. In this review, we describe current knowledge pertaining to mechanisms and regulation of angiogenesis in ovarian carcinomas with special reference to our recent research results.
Ueda
Masatsugu
M
Department of Obstetrics and Gynecology, Osaka Medical College, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan. gyn017@poh.osaka-med.ac.jp
Terai
Yoshito
Y
Kanda
Koji
K
Kanemura
Masanori
M
Takehara
Mikio
M
Futakuchi
Hikari
H
Yamaguchi
Hiroyuki
H
Yasuda
Masayuki
M
Nishiyama
Koji
K
Ueki
Minoru
M
D043925:Angiogenesis Inducing Agents; D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D042501:Angiogenic Proteins / Q000235:genetics / Q000502:physiology; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002277:Carcinoma / Q000098:blood supply* / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D049109:Cell Proliferation; D016326:Extracellular Matrix Proteins; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D015316:Genetic Therapy; D006801:Humans; D020778:Matrix Metalloproteinase 2 / Q000235:genetics / Q000502:physiology; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009389:Neovascularization, Pathologic / Q000235:genetics*; D010051:Ovarian Neoplasms / Q000098:blood supply* / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use; D016337:RNA, Catalytic / Q000494:pharmacology / Q000627:therapeutic use; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology
D043925:Angiogenesis Inducing Agents; D020533:Angiogenesis Inhibitors; D042501:Angiogenic Proteins; C121301:Angiozyme; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016326:Extracellular Matrix Proteins; D010455:Peptides; D016337:RNA, Catalytic; C429104:SPON1 protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D020778:Matrix Metalloproteinase 2